文献速递分子诊断临床血液与体液

二代测序在临床血液肿瘤筛查与评估中的价值

The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
PubMed 文献 · Am J Clin Pathol · 2020-01-01

该研究采用靶向二代测序面板评估178例疑似或已诊断髓系肿瘤患者,53%检出基因变异,29%为新发变异,34%为意义不明变异;骨髓样本变异数高于外周血,且二代测序比常规细胞遗传学更敏感,在筛查、诊断、预后分层和随访中起关键作用。

要点

  • 二代测序在53%的髓系肿瘤患者中检出基因变异。
  • 骨髓样本比外周血检出更多变异,且二代测序比常规细胞遗传学更敏感。
  • 二代测序可用于髓系肿瘤的筛查、诊断、预后分层和随访。

核心结论

  • 二代测序是评估疑似和确诊血液肿瘤的有效工具,可成为患者常规检查的一部分。

研究设计与样本

  • 采用靶向二代测序面板评估178例疑似或已诊断髓系肿瘤患者。

主要发现

  • 53%的患者检出基因变异。
  • 29%的患者检出新颖变异,34%检出意义不明变异。
  • 骨髓样本检出的变异数高于外周血。
  • 二代测序比常规细胞遗传学更敏感。
  • 在多种髓系肿瘤的筛查、诊断、预后分层和临床随访中,二代测序起关键作用。

临床怎么用

  • 二代测序可用于疑似或确诊髓系肿瘤的筛查、诊断、预后分层和随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The implementation of next-generation sequencing (NGS) in routine clinical hematology practice remains limited. We evaluate the clinical value of NGS in the screening, diagnosis, and follow-up in hematologic neoplasms. METHODS: A targeted NGS panel was used to assess a total of 178 patients for questionable or previously diagnosed myeloid neoplasms. RESULTS: Gene variants were identified in 53% of patients. Novel variants were identified in 29% of patients and variants of unknown significance in 34%. Bone marrow samples yielded a higher number of variants than in peripheral blood. NGS is a more sensitive test than conventional cytogenetics. In several cases, NGS played a key role in the screening, diagnostics, prognostic stratification, and the clinical follow-up of a wide variety of myeloid neoplasms. CONCLUSIONS: NGS is an effective tool in the evaluation of suspected and confirmed hematologic neoplasms and could become part of the routine workup of patients.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Northrup V, Maybank A, Carson N, et al. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice. Am J Clin Pathol. 2020. PMID: 31875888. doi:10.1093/ajcp/aqz203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。